E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist
Beau Norgeot,Giorgio Quer,Brett K. Beaulieu-Jones,Ali Torkamani,Raquel Dias,Milena A. Gianfrancesco,Rima Arnaout,Isaac S. Kohane,Suchi Saria,Eric J. Topol,Ziad Obermeyer,Bin Yu,Atul J. Butte +12 more
TL;DR: The MI-CLAIM checklist is presented, a tool intended to improve transparent reporting of AI algorithms in medicine and to improve transparency in the evaluation of algorithms used in medicine.
Journal ArticleDOI
Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease Results From the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial
Peter B. Berger,Deepak L. Bhatt,Valentin Fuster,P. Gabriel Steg,Keith A.A. Fox,Mingyuan Shao,Danielle M. Brennan,Werner Hacke,Gilles Montalescot,Steven R. Steinhubl,Eric J. Topol +10 more
TL;DR: In the CHARISMA trial, there was an increased risk of bleeding with long-term clopidogrel and moderate bleeding was strongly associated with mortality.
Journal ArticleDOI
Selection of Patients with Acute Myocardial Infarction for Thrombolytic Therapy
David W.M. Muller,Eric J. Topol +1 more
TL;DR: The data do not support the use of fibrinolytic therapy as primary treatment in patients with unstable angina or suspected myocardial infarction in the absence of confirmatory electrocardiographic changes, and the potential benefits of this treatment might be extended to selected high-risk subgroups.
Journal ArticleDOI
Clinical and Therapeutic Profile of Patients Presenting With Acute Coronary Syndromes Who Do Not Have Significant Coronary Artery Disease
Matthew T. Roe,RA Harrington,D M Prosper,Karen S. Pieper,Deepak L. Bhatt,A.M. Lincoff,Maarten L. Simoons,Martijn Akkerhuis,Erik Magnus Ohman,Michael M. Kitt,A Vahanian,Witold Rużyłło,Karl R. Karsch,Robert M. Califf,Eric J. Topol +14 more
TL;DR: In this article, the authors identified independent baseline predictors of insignificant coronary artery disease (mild or no CAD) and used them to develop a simple predictive nomogram of the probability of insignificant CAD for use at a hospital presentation, which can be used to determine indications for glycoprotein IIb/IIIa blockade.
Journal ArticleDOI
Sustained ventricular arrhythmias in patients receiving thrombolytic therapy : Incidence and outcomes
Keith H. Newby,Trevor D. Thompson,Amanda Stebbins,Eric J. Topol,Robert M. Califf,Andrea Natale +5 more
TL;DR: Sustained ventricular tachycardia (VT) and fibrillation (VF) occur in up to 20% of patients with acute myocardial infarction (MI) and have been associated with a poor prognosis as discussed by the authors.